Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years, excluding those with tricuspid valves. This study included low surgical risk patients with severe aortic stenosis and symptoms, 75 years or younger. Participants were randomized 1:1 to receiving TAVR or SAVR, stratified according to sex, need for new...
EuroPCR 2024 | SOLVE-TAVI: Self Expanding or Balloon Expandable Valves?
This was a randomized study with 447 patients carried out to compare the 5-year evolution of TAVR using Evolut R and SAPIEN 3, as well as general anesthesia vs. conscious sedation. Randomization was in two stages: first valve selection and later the anesthesia technique, that is, conscious sedation vs general anesthesia. The populations were similar....
Acute Myocardial Infarction After TAVI: Retrospective Analysis of >200,000 Implants
Coronary artery disease is common among patients considered for transcatheter aortic valve implantation (TAVI). With the expansion of the indication for TAVI to a population with lower surgical risk, and therefore younger, there has been a gradual increase in the incidence of coronary events. However, there is limited data on treatment strategy and outcomes in...
Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study
Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation...
Should We Treat Obstructive Coronary Artery Disease in TAVI?
Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the...
TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology | SOLACI-SBHCI 2023
✔️ SOLACI-SBHCI 2023 – International Live Case | TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology ✔️ Site: Nanjing First Hospital, Nanjing, China ✔️ August 4, 2023, Copacabana Room, Windsor Oceánico
TAVI with Venus-Vitae | SOLACI-SBHCI 2023 – Live Case Transmission
✔️ SOLACI-SBHCI 2023 – International Live Case | TAVI with Venus-Vitae. ✔️ Site: Corrientes, Argentina. ✔️ August 2, 2023, Barra de Tijuca Room, Windsor Oceánico.
MINIMALISTIC TAVI Using CUSP-OVERLAP Technique | SOLACI-SBHCI 2023 – National Live Case
✔️ SOLACI-SBHCI 2023 – National Live Case | Minimalistic TAVI using cusp-overlap technique ✔️ Site: INSTITUTO NACIONAL DE CARDIOLOGIA (INC) ✔️ August 3, 2023, Copacabana Room, Windsor Oceánico
TAVI with Commissural Alignment & Cerebral Protection | SOLACI-SBHCI 2023, International Live Case
✔️ SOLACI-SBHCI 2023 – Internationl Live Case | TAVI with Commissural Alignment & Cerebral Protection ✔️ Site; LEIPZIG HEART CENTER – LEIPZIG, GERMANY ✔️ August 3, 2023, Copacabana Room, Windsor Oceánico
TAVI Tailored Intermediate Bioprosthesis Sizes | SOLACI-SBHCI 2023 – National Live Case
✔️ SOLACI-SBHCI 2023 – National Live Case | TAVI Tailored Intermediate Bioprosthesis Sizes ✔️ Site; INSTITUTO ESTADUAL DE CARDIOLOGIA ALOYSIO DE CASTRO (IECAC) ✔️August 2, 2023, Copacabana Room, Windsor Oceánico